Max Higgins, Consultant, Author at EverGlade Consulting

Max Higgins, Consultant

Max Higgins, Consultant
BARDA pandemic influenza vaccine partnerships

BARDA Seeks Industry Input for Pandemic Influenza Vaccine Partnerships

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a new Sources Sought Notice (SSN) and Request for Information (RFI) focused on vaccine medical countermeasures (MCMs) for pandemic influenza preparedness and response. This initiative underscores BARDA’s ongoing commitment to strengthening the nation’s biosecurity […]

BARDA Seeks Industry Input for Pandemic Influenza Vaccine Partnerships Read More »

BARDA RAPID RFI antibodies

BARDA’s RAPID RFI for Next-Generation Antibody Design through Production

BARDA RAPID RFI RAPID Overview The Biomedical Advanced Research and Development Authority (BARDA) has issued a new Request for Information (RFI) titled “Rapid Antibody Production for Immunoassay Diagnostics (RAPID)”. Through this RFI, BARDA seeks to more deeply understand causes of existing bottlenecks in the antibody generation process (design through production) and assess the R&D landscape

BARDA’s RAPID RFI for Next-Generation Antibody Design through Production Read More »

JPEO RFI genetic sequencing

JPEO-CBRND Seeks Next-Generation Genomic Sequencing Capabilities for the Battlefield

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) has released a new Request for Information (RFI) titled “End-to-End Untargeted Genomic Sequencing Workflows Appropriate for Military Use.” This RFI underscores the Department of Defense’s (DoD) growing emphasis on rapid, field-deployable biological threat detection, a critical component of maintaining operational readiness in

JPEO-CBRND Seeks Next-Generation Genomic Sequencing Capabilities for the Battlefield Read More »

BARDA advancing pathogen agnostic diagnostics

Advancing Pathogen-Agnostic Diagnostics

BARDA RRPV-26-09-AgDx Request for Project Proposals The Biomedical Advanced Research and Development Authority (BARDA) has released a new Request for Project Proposals (RPP-26-09-AgDx) through the Rapid Response Partnership Vehicle (RRPV), seeking to revolutionize the nation’s diagnostic readiness for infectious disease threats. Managed by Advanced Technology International (ATI), the RRPV enables collaboration between industry, academia, and

Advancing Pathogen-Agnostic Diagnostics Read More »

DARPA smart red cells program

DARPA’s Smart Red Blood Cells Program: Engineering the Future of Human Performance

DARPA-PS-26-02 (Smart Red Blood Cells Program) The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has announced a groundbreaking solicitation titled DARPA-PS-26-02: Smart Red Blood Cells (Smart-RBC) to redefine human performance in extreme environments. This program seeks to leverage advances in synthetic biology and bioengineering to create red blood cells (RBCs)

DARPA’s Smart Red Blood Cells Program: Engineering the Future of Human Performance Read More »

BARDA’s RPP to Onshore Vaccine Manufacturing for Viral Hemorrhagic Fevers

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has issued a new Request for Project Proposals (RPP-26-10-VHF) under its Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). This solicitation represents a key step in building domestic capacity for advanced vaccine manufacturing to strengthen the nation’s biosecurity infrastructure.

BARDA’s RPP to Onshore Vaccine Manufacturing for Viral Hemorrhagic Fevers Read More »

Medicine capsules global health with geometric pattern digital r

ARPA-H’s Proactive Health Office ISO

PROACTIVE HEALTH OFFICE – MISSION OFFICE INNOVATIVE SOLUTIONS OPENING (ISO) – ARPA-H-SOL-24-106 – Amendment 03: October 14, 2025 Building a Healthier Future Through Prevention The Advanced Research Projects Agency for Health (ARPA-H), a key innovation agency within the U.S. Department of Health and Human Services, has released an updated solicitation for its Proactive Health Office

ARPA-H’s Proactive Health Office ISO Read More »

DARPA Disruptioneering Program

DARPA’s Disruptioneering Program

DARPA Disruptioneering Program Announcement 25-07 The Defense Advanced Research Projects Agency (DARPA), through its Defense Sciences Office (DSO), has released its latest Disruptioneering Program Announcement (DARPA-PA-25-07). Published on September 30, 2025, this initiative aims to accelerate the agency’s ability to fund and execute high-risk, high-reward scientific research. At its core, the Disruptioneering program establishes a

DARPA’s Disruptioneering Program Read More »

DARPA’s Biological Technologies Office Broad Agency Announcement

DARPA BTO Broad Agency Announcement 10.25 The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has released a new Broad Agency Announcement (BAA), HR001126S0003, on October 1, 2025. This solicitation seeks transformative research leveraging biological processes and technologies to enhance warfighter protection and performance. DARPA BTO continues to push the boundaries

DARPA’s Biological Technologies Office Broad Agency Announcement Read More »

HHS Operations During A Government Shutdown

When the federal government faces a lapse in appropriations, agencies across the Department of Health and Human Services (HHS) must implement contingency plans to sustain critical activities. Both the Advanced Research Projects Agency for Health (ARPA-H) and the Administration for Strategic Preparedness and Response (ASPR), which houses the Biomedical Advanced Research and Development Authority (BARDA),

HHS Operations During A Government Shutdown Read More »

ARPA-H THRIVE ISO

ARPA-H THRIVE_ISO_Final_16092025 Transforming Genetic Medicine for Rare Diseases: ARPA-H’s THRIVE Initiative The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has announced the Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) Innovative Solutions Opening (ISO) (ARPA-H-SOL-25-122). The initiative represents a bold step toward curative genetic medicines that

ARPA-H THRIVE ISO Read More »

ARPA-H GIVE Initiative to Transform Genetic Medicine Manufacturing

ARPA-H 4.0_GIVE_ISO_20250925 Revolutionizing Biomanufacturing for Personalized Genetic Medicines The Advanced Research Projects Agency for Health (ARPA-H), through its Scalable Solutions Office (SSO), has released an Innovative Solutions Opening (ISO) titled Genetic Medicines and Individualized Manufacturing for Everyone (GIVE). This bold initiative seeks to accelerate U.S. leadership in biomanufacturing by enabling distributed, on-demand, and individualized production

ARPA-H GIVE Initiative to Transform Genetic Medicine Manufacturing Read More »

Scroll to Top